UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $158.72, but opened at $150.53. UCB shares last traded at $151.3950, with a volume of 26,509 shares.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on UCBJY. Wolfe Research raised UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Zacks Research cut UCB from a “hold” rating to a “strong sell” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, UCB currently has an average rating of “Buy”.
Get Our Latest Stock Analysis on UCBJY
UCB Stock Down 5.0%
UCB Company Profile
UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.
The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.
Further Reading
- Five stocks we like better than UCB
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
